5 Lipoxygenase (ALOX5) Human shRNA Plasmid Kit (Locus ID 240)

Specifications

Product Data
Product Name	5 Lipoxygenase (ALOX5) Human shRNA Plasmid Kit (Locus ID 240)
Locus ID	240
UniProt ID	P09917
Synonyms	5-LO; 5-LOX; 5LPG; LOG5
Vector	pGFP-C-shLenti
Format	Lentiviral plasmids
Kit Components	ALOX5 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 240). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.
RefSeq	NM_000698, NM_001256153, NM_001256154, NM_001320861, NM_001320862, NM_000698.1, NM_000698.2, NM_000698.3, NM_000698.4, NM_001256154.1, NM_001256154.2, NM_001256153.1, NM_001256153.2, BC034464, BC040450, BC130332, BC132677, BC143985, BC143986, BM153780, NM_001256153.3, NM_000698.5
Summary	This gene encodes a member of the lipoxygenase gene family and plays a dual role in the synthesis of leukotrienes from arachidonic acid. The encoded protein, which is expressed specifically in bone marrow-derived cells, catalyzes the conversion of arachidonic acid to 5(S)-hydroperoxy-6-trans-8,11,14-cis-eicosatetraenoic acid, and further to the allylic epoxide 5(S)-trans-7,9-trans-11,14-cis-eicosatetrenoic acid (leukotriene A4). Leukotrienes are important mediators of a number of inflammatory and allergic conditions. Mutations in the promoter region of this gene lead to a diminished response to antileukotriene drugs used in the treatment of asthma and may also be associated with atherosclerosis and several cancers. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jan 2012]
shRNA Design	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
Performance Guaranteed	OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).

*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.